A significant controversy is brewing within the medical community regarding the timing of the hepatitis B vaccine for newborns. A key federal vaccine advisory panel, recently reshaped under Health Secretary Robert F. Kennedy Jr.'s leadership, is poised to vote on a proposal to delay the first dose of the vaccine until age four. This recommendation starkly contrasts with the current CDC guideline of administering the vaccine before newborns leave the hospital.
Former senior CDC officials express deep concern over this potential shift. They highlight the potential for a dramatic increase in hepatitis B cases among children, a disease that has been largely eradicated in the American pediatric population thanks to the current vaccination strategy. The proposed delay, they argue, undermines decades of successful public health efforts. Experts emphasize that the current universal approach prevents cases where testing might be inaccurate or mothers may have unknowingly contracted the virus.
The decision is expected to be made during the CDC's Advisory Committee on Immunization Practices (ACIP) meeting scheduled for September 18-19. The lack of thorough data analysis prior to the proposed change is particularly troubling for many pediatricians. The urgency of the proposed change and lack of prior data analysis raise concerns among medical professionals. The previous 30-year-long practice of vaccinating newborns at birth has yielded a 99% decrease in Hepatitis B cases in those under 19 since 1990.
Beyond the hepatitis B vaccine, the ACIP will also discuss recommendations for other crucial vaccines, including the MMRV (measles, mumps, rubella, and varicella) and COVID-19 vaccines. Changes to vaccination schedules could significantly impact access to these vaccines for many families, as ACIP recommendations often dictate insurance coverage and federal program eligibility. This concern has added fuel to the anxieties surrounding the potential delay in the hepatitis B vaccine.
While a Health and Human Services spokesperson claims that ACIP will rely on the "best available evidence," critics point to a lack of transparent data analysis and a potential political influence shaping the decision-making process. This lack of transparency is alarming, considering the potential for widespread health consequences if universal newborn vaccination for hepatitis B is discontinued. The current administration's emphasis on this specific vaccine change is viewed by many as concerning. Many fear that the delay in the vaccine may lead to an increase in chronic cases of Hepatitis B with the potential for far more severe long-term consequences. The long-term impact on public health and healthcare access are central concerns of medical professionals and advocates.
Individuals who have lived with the chronic effects of hepatitis B are also voicing their strong opposition to the proposed change. They share harrowing stories of the disease's long-term effects and the importance of preventative measures, underscoring the critical need for maintaining current vaccination practices. The potential consequences extend to increased risks of liver damage, liver cancer, and the potential to transmit the disease to others. This underscores the potentially devastating impact of a policy change that could unravel decades of progress in combating this disease.
---
Originally published at: https://www.npr.org/sections/shots-health-news/2025/09/16/nx-s1-5542405/rfk-jr-acip-vaccine-advisory-panel-vote-delay-hepatitis-b-shot-in-infants
